Clene Inc. (NASDAQ: CLNN) is a biotechnology company focused on developing innovative treatments for neurodegenerative diseases. The company is known for its pioneering work in nanotherapeutics, which involves using nanotechnology to create new medical treatments. Clene's competitors include other biotech firms working on similar therapies, such as Biogen and Novartis.
On January 7, 2026, Ugwumba Chidozie, a significant shareholder of CLNN, sold 3,938 shares at $6.29 each. This transaction is part of a series of sales by Chidozie, who previously sold 4,138 shares on December 30th at $6.03, totaling approximately $24,952. These sales are part of routine portfolio management for large shareholders.
Following the January 7th transaction, Chidozie holds 753,562 shares of CLNN. This is a slight decrease from the 783,590 shares he held after the December 30th sale. Despite these sales, Chidozie remains a major shareholder, with his holdings valued at around $4.7 million, reflecting his continued confidence in the company's potential.
The current price of CLNN is $6.28, showing a 2.28% increase. The stock has fluctuated between $6.06 and $6.56 today. Over the past year, CLNN's price ranged from a high of $13.50 to a low of $2.28. The company's market capitalization is approximately $58.4 million, with a trading volume of 51,957 shares on the NASDAQ exchange.
